Related references
Note: Only part of the references are listed.Rare genetic variants in cellular transporters, metabolic enzymes, and nuclear receptors can be important determinants of interindividual differences in drug response
Mikael Kozyra et al.
GENETICS IN MEDICINE (2017)
Prediction of CYP2D6 phenotype from genotype across world populations
Andrea Gaedigk et al.
GENETICS IN MEDICINE (2017)
Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for Pharmacogenetics-Guided Warfarin Dosing: 2017 Update
J. A. Johnson et al.
CLINICAL PHARMACOLOGY & THERAPEUTICS (2017)
High Frequency of CYP2D6 Ultrarapid Metabolizer Genotype in the Finnish Population
Paavo Pietarinen et al.
BASIC & CLINICAL PHARMACOLOGY & TOXICOLOGY (2016)
The Importance of Patient-Specific Factors for Hepatic Drug Response and Toxicity
Volker M. Lauschke et al.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES (2016)
Analysis of protein-coding genetic variation in 60,706 humans
Monkol Lek et al.
NATURE (2016)
Patterns of genic intolerance of rare copy number variation in 59,898 human exomes
Douglas M. Ruderfer et al.
NATURE GENETICS (2016)
Requirements for comprehensive pharmacogenetic genotyping platforms
Volker M. Lauschke et al.
PHARMACOGENOMICS (2016)
Precision Medicine and Rare Genetic Variants
Volker M. Lauschke et al.
TRENDS IN PHARMACOLOGICAL SCIENCES (2016)
A global reference for human genetic variation
David M. Altshuler et al.
NATURE (2015)
Pharmacogenomic information in drug labels: European Medicines Agency perspective
F. Ehmann et al.
PHARMACOGENOMICS JOURNAL (2015)
Whole-Exome Sequencing Reveals Defective CYP3A4 Variants Predictive of Paclitaxel Dose-Limiting Neuropathy
Maria Apellaniz-Ruiz et al.
CLINICAL CANCER RESEARCH (2015)
High frequency and founder effect of the CYP3A4*20 loss-of-function allele in the Spanish population classifies CYP3A4 as a polymorphic enzyme
M. Apellaniz-Ruiz et al.
PHARMACOGENOMICS JOURNAL (2015)
CYP2A7 Pseudogene Transcript Affects CYP2A6 Expression in Human Liver by Acting as a Decoy for miR-126☆
Masataka Nakano et al.
DRUG METABOLISM AND DISPOSITION (2015)
Genotype-Guided vs Clinical Dosing of Warfarin and Its Analogues Meta-analysis of Randomized Clinical Trials
Kathleen Stergiopoulos et al.
JAMA INTERNAL MEDICINE (2014)
Kinetic Interpretation of the Importance of OATP1B3 and MRP2 in Docetaxel-Induced Hematopoietic Toxicity
A. Yamada et al.
CPT-PHARMACOMETRICS & SYSTEMS PHARMACOLOGY (2014)
UDP-glucuronosyltransferase 2B17 genotype and the risk of lung cancer among Austrian Caucasians
Michaela Gruber et al.
CANCER EPIDEMIOLOGY (2013)
UDP-glucuronosyltransferase 2B17 genotyping in Japanese athletes and evaluation of the current sports drug testing for detecting testosterone misuse
Masato Okano et al.
DRUG TESTING AND ANALYSIS (2013)
Detection of Clinically Relevant Copy Number Variants with Whole-Exome Sequencing
Joep de Ligt et al.
HUMAN MUTATION (2013)
A Pharmacogenetic versus a Clinical Algorithm for Warfarin Dosing
Stephen E. Kimmel et al.
NEW ENGLAND JOURNAL OF MEDICINE (2013)
A Randomized Trial of Genotype-Guided Dosing of Warfarin
Munir Pirmohamed et al.
NEW ENGLAND JOURNAL OF MEDICINE (2013)
Multi-ethnic cytochrome-P450 copy number profiling: novel pharmacogenetic alleles and mechanism of copy number variation formation
S. Martis et al.
PHARMACOGENOMICS JOURNAL (2013)
Pharmacogenomics of drug-metabolizing enzymes: a recent update on clinical implications and endogenous effects
S. C. Sim et al.
PHARMACOGENOMICS JOURNAL (2013)
Evolution and Functional Impact of Rare Coding Variation from Deep Sequencing of Human Exomes
Jacob A. Tennessen et al.
SCIENCE (2012)
Human Copy Number Variation and Complex Genetic Disease
Santhosh Girirajan et al.
ANNUAL REVIEW OF GENETICS, VOL 45 (2011)
Global patterns of genetic diversity and signals of natural selection for human ADME genes
Jing Li et al.
HUMAN MOLECULAR GENETICS (2011)
The impact of pharmacogenetics of metabolic enzymes and transporters on the pharmacokinetics of telmisartan in healthy volunteers
Akihiro Yamada et al.
PHARMACOGENETICS AND GENOMICS (2011)
Copy number variants in pharmacogenetic genes
Yijing He et al.
TRENDS IN MOLECULAR MEDICINE (2011)
Influence of CYP2D6 Deletion, Multiplication,-1584C -> G, 31G -> A and 2988G -> A Gene Polymorphisms on Dextromethorphan Metabolism among Mexican Tepehuanos and Mestizos
Martha Sosa-Macias et al.
PHARMACOLOGY (2010)
Impact of OATP transporters on pharmacokinetics
A. Kalliokoski et al.
BRITISH JOURNAL OF PHARMACOLOGY (2009)
Common variants in the SLCO1B3 locus are associated with bilirubin levels and unconjugated hyperbilirubinemia
Serena Sanna et al.
HUMAN MOLECULAR GENETICS (2009)
Adverse Drug Reactions in Hospital In-Patients: A Prospective Analysis of 3695 Patient-Episodes
Emma C. Davies et al.
PLOS ONE (2009)
A genome-wide scan for common genetic variants with a large influence on warfarin maintenance dose
Gregory M. Cooper et al.
BLOOD (2008)
Pharmacogenomic biomarker information in drug labels approved by the United States Food and Drug Administration: Prevalence of related drug use
Felix W. Frueh et al.
PHARMACOTHERAPY (2008)
Medication use leading to emergency department visits for adverse drug events in older adults
Daniel S. Budnitz et al.
ANNALS OF INTERNAL MEDICINE (2007)
Global variation in copy number in the human genome
Richard Redon et al.
NATURE (2006)
Predominant contribution of OATP1B3 to the hepatic uptake of telmisartan, an angiotensin II receptor antagonist, in humans
Naoki Ishiguro et al.
DRUG METABOLISM AND DISPOSITION (2006)
Common deletion polymorphisms in the human genome
SA McCarroll et al.
NATURE GENETICS (2006)
Incidence of adverse drug reactions in paediatric in/out-patients: a systematic review and meta-analysis of prospective studies
P Impicciatore et al.
BRITISH JOURNAL OF CLINICAL PHARMACOLOGY (2001)
Clinical application of pharmacogenetics
BB Spear et al.
TRENDS IN MOLECULAR MEDICINE (2001)
Share Paper
